Evaluating Aranesp® for the Treatment of Anemia in African-American Subjects With Chronic Renal Failure (CRF) Receiving Hemodialysis

• Status: Completed
• Trial end date: 1969-12-31

Summary

This study is designed to evaluate the hemoglobin response to Aranesp® (darbepoetin alfa) in black subjects (African-Americans) with chronic renal failure (CRF) receiving hemodialysis and to examine the safety profile.

• Phase: Phase 4

Details

• Lead Sponsor: Amgen
• Treatments: Darbepoetin alfa